News & events

Press releases

8 October 2019, Sophia Antipolis, France

Median Technologies’ Q3 performance shows steady growth, validates the strategy adopted in 2018 (unaudited figures)

Median Technologies’ Q3 performance shows steady growth, validates the strategy adopted in 2018 (unaudited figures). As of September 30th, 2019, cumulated revenue of € 6.3 million, already matching total revenue made in 2018 – Q3 revenue of € 2.3 million, a steady increase over the last four quarters – Order backlog of € 35.9 million, up 17% since June 30th, 2019 – Cash and cash equivalents of € 8.3 million, an increase compared to June 30th, 2019

Read more
See all press releases

Conferences

September 27 - October 1, 2019 | Barcelona, Spain

ESMO 2019

Median will be exhibiting at the ESMO Congress 2019, which will take place from September 27 to Octiber 1st in Barcelona, Spain. Stop by our booth #460, Hall 3 to learn more about our breakthrough imaging solutions and services for oncology clinical trials and our Imaging Phenomics platform iBiopsy®. Happy to see you there during the whole exhibition duration, from September 27 to September 30.

Visit conference website
See all conferences

In the press

iBiopsy® for Precision Medicine

Check out our paper published in the European Medical Journal on December 13, 2018 in order to educate the oncology specialists across Europe and the US as to the high-throughput artificial intelligence powered image-base phenotyping platform, iBiopsy® -> http://viewer.zmags.com/publication/647c38a3#/647c38a3/50

Abstract

A high-throughput artificial intelligence-powered image-based phenotyping platform, iBiopsy® (Median Technologies, Valbonne, France), which aims to improve precision medicine, is discussed in the presented review. The article introduces novel concepts, including high-throughput, fully automated imaging biomarker extraction; unsupervised predictive learning; large-scale content-based image-based similarity search; the use of large-scale clinical data registries; and cloud-based big data analytics to the problems of disease subtyping and treatment planning. Unlike electronic health record-based approaches, which lack the detailed radiological, pathological, genomic, and molecular data necessary for accurate prediction, iBiopsy® generates unique signatures as fingerprints of disease and tumor subtypes from target images. These signatures are then merged with any additional omics data and matched against a large-scale reference registry of deeply phenotyped patients. Initial applications targeted include hepatocellular carcinoma and other chronic liver diseases, such as nonalcoholic steatohepatitis. This new disruptive technology is expected to lead to the identification of appropriate therapies targeting specific molecular pathways involved in the detected phenotypes to bring personalised treatment to patients, taking into account individual biological variability, which is the principal aim of precision medicine.

See all in the press

Blog

See all blog entries